Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IKBKB | O14920 | 2/20 | 0.35 |
| ▸ | CHUK | O15111 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | CHKA | P35790 | 1/20 | 0.33 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.32 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.32 |
| ▸ | DAO | P14920 | 1/20 | 0.32 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.31 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.31 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.31 |
| ▸ | GFER | P55789 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3345196 | 0.84 | MAOB (0.43) | MEN1ALDH1A1MAPTKMT2ADAO | |
| SCHEMBL16690706 | 0.81 | MAOB (0.44) | MEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL16689472 | 0.80 | AR (0.41) | ALDH1A1S1PR1 | |
| SCHEMBL16689467 | 0.77 | IKBKB (0.41) | IKBKBCHUKMEN1ALDH1A1MAPT | |
| SCHEMBL1974446 | 0.74 | ALDH1A1 (0.38) | IKBKBMEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL11811716 | 0.71 | ALDH1A1 (0.44) | MEN1ALDH1A1MAPTKMT2ANPSR1 | |
| SCHEMBL3301918 | 0.70 | ADORA1 (0.46) | MEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL4840749 | 0.70 | GAA (0.41) | IKBKBMEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL28846698 | 0.70 | — | — | |
| SCHEMBL23827482 | 0.69 | ALDH1A1 (0.40) | MEN1ALDH1A1MAPTKMT2ANPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9278958-B2 | Anti-cancer compounds | KATHOLIEKE UNIVERSITEIT LEUVEN K.U. LEUVEN R&D (BE) | 2016-03-08 | — | — | US | disclosed |
| US-20150126559-A1 | NOVEL ANTI-CANCER COMPOUNDS | UNIVERSITA DEGLI STUDI DI FERRARA (IT) | 2015-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150126559-A1 | NOVEL ANTI-CANCER COMPOUNDS | ATP5F1A, TP53, ABCF1 | IKBKB 1110/4885CHUK 1233/4885MEN1 1180/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.